U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07110584) titled 'Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors' on July 24.
Brief Summary: This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2004 in patients with advanced tumors.
Study Start Date: Sept. 30
Study Type: INTERVENTIONAL
Condition:
Advanced Tumors
Intervention:
DRUG: MDX2004
MDX2004 intravenous infusion
Recruitment Status: NOT_YET_RECRUITING
Sponsor: ModeX Therapeutics, An OPKO Health Company
Disclaimer: Curated by HT Syndication....